John L. Higgins - Nov 17, 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Signature
/s/ Andrew Reardon, Attorney-in-Fact for John L. Higgins
Stock symbol
LGND
Transactions as of
Nov 17, 2022
Transactions value $
-$655,373
Form type
4
Date filed
11/21/2022, 06:04 PM
Previous filing
Nov 3, 2022
Next filing
Dec 1, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Sale -$783K -10K -2.34% $78.32 417K Nov 17, 2022 Direct F1
transaction LGND Common Stock Options Exercise $128K +10K +2.4% $12.78* 427K Nov 18, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Non-Qualified Stock Option (right to buy) Options Exercise $0 -10K -19.87% $0.00 40.3K Nov 18, 2022 Common Stock 10K $12.78 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on September 22, 2022, in accordance with Rule 10b5-1.
F2 Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The original date of grant was 02/15/13.